Results 141 to 150 of about 36,913 (263)

Epilepsy surgery: From bench to the clinics

Epilepsia Open, EarlyView.
Abstract Objective Recent advances in epilepsy surgery in patients with intractable epilepsy make it possible to study the mechanism of epilepsy in human brains. However, the true extent and propagation of each epileptogenic area from the epileptogenic focus in each patient is still difficult to perform “epilepsy cure” by surgery.
Tatsuya Tanaka
wiley   +1 more source

”Not always the magic bullet”—Insufficient seizure control by ketogenic dietary therapies in Glut1 Deficiency Syndrome

Epilepsia Open, Volume 11, Issue 3, Page 847-858, June 2026.
Abstract Objective Ketogenic dietary therapies (KDTs) are the treatment of choice for Glut1 Deficiency Syndrome (Glut1DS), providing dietary ketones as an alternative fuel to the brain and effectively controlling seizures. Recent evidence indicates insufficient seizure control in Glut1DS patients despite adequate KDT and ketosis.
Joerg Klepper, Eva Runkel, Lucia Kiesel
wiley   +1 more source

Audio-visual stimulation therapy for chronic neuropathic pain: a sham-controlled randomized clinical trial. [PDF]

BMC Neurol
Tabacof L, Howard R, Bower J, Canori A, Bond N, Breyman E, Dewil S, Tosto-Mancuso J, Hanbury R, Carmouche B, Robberson M, Fry A, Putrino D.   +12 more
europepmc   +1 more source

ILAE dietary treatments task force special report: Maternal ketogenic diet exposure in epilepsy pregnancy registries—A call to action

Epilepsia Open, Volume 11, Issue 3, Page 702-709, June 2026.
Abstract Ketogenic dietary therapies (KDTs) are increasingly used worldwide as a non‐pharmacological treatment for epilepsy, including among people of childbearing potential. In many cases, KDTs allow for the reduction of antiseizure medications (ASMs) and lower drug exposure during pregnancy.
Magnhild Kverneland, Valentina De Giorgis, Laura Healy, Kelly Faltersack, Tanya J. W. McDonald, Marisa Armeno, Mackenzie C. Cervenka, Anita Devlin   +7 more
wiley   +1 more source

Retention rates of antiepileptic drugs in glioma patients: the most appropriate outcome

CNS Oncology, 2020
Pim B van der Meer, Linda Dirven, Marta Fiocco, Martin JB Taphoorn, Johan AF Koekkoek   +4 more
doaj   +1 more source

A Narrative Review of Drug-Induced Haemophagocytic Lymphohistiocytosis: A Rare but Relevant Differential Diagnosis.

Int Arch Allergy Immunol
Ali SB, King J, Lucas M.
europepmc   +1 more source

Medication Prescribing Observations in Care Transitions for Incarcerated Patients. [PDF]

Hosp Pharm
Shoulders BR, Maguigan KL, Lemon SJ.
europepmc   +1 more source

Perampanel as add‐on in high‐grade glioma–related epilepsy: Seizure control and QoL in a prospective, multicenter, real‐world 6‐month follow‐up study

Epilepsia Open, EarlyView.
Abstract Objective High‐grade astrocytomas, including glioblastomas, are aggressive brain tumors with poor prognosis and a 5‐year survival below 7%. Seizures affect up to 75% of glioma patients, especially in low‐grade tumors but also in high‐grade cases.
Matteo Impellizzeri, Paolo Paone, Giada Pauletto, Annacarmen Nilo, Simone Beretta, Andrea Salmaggi, Stefano Consoli, Stefano Quadri   +7 more
wiley   +1 more source

Editorial: Experimental Models of Epilepsy and Related Comorbidities

Frontiers in Pharmacology, 2019
Ayanabha Chakraborti, Mohd. Farooq Shaikh, Annamaria Vezzani, Jafri Malin Abdullah   +3 more
doaj   +1 more source

An Evaluation of the Real-World Effectiveness of Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. [PDF]

Neurol Ther
Hubsch A, Divino V, Mallick R, Coyle KB, Langford E, Wang Y, Ida F, Lahue BJ, Zhang X.   +8 more
europepmc   +1 more source